# An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer

> **NCT03243331** · PHASE1 · COMPLETED · sponsor: **Kathy Miller** · enrollment: 18 (actual)

## Conditions studied

- Triple Negative Breast Cancer
- Metastatic Breast Cancer

## Interventions

- **DRUG:** Gedatolisib
- **DRUG:** PTK7-ADC

## Key facts

- **NCT ID:** NCT03243331
- **Lead sponsor:** Kathy Miller
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-19
- **Primary completion:** 2020-05-27
- **Final completion:** 2020-05-27
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2021-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03243331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03243331, "An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03243331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*